1. Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV) in Patients with Malignancy
- Author
-
Babak PeyroShabany, Mansoureh Dehghani, Seyed Alireza Javadinia, Danial Fazilat-Panah, Pejman Porouhan, Farbod Hatami, James S Welsh, Maryam Nabavifard, Mona Ariamanesh, and Mohammad Fereidouni
- Subjects
Adult ,Male ,Cancer Research ,COVID-19 Vaccines ,Adolescent ,medicine.medical_treatment ,anticancer treatment ,Malignancy ,Young Adult ,Immunogenicity, Vaccine ,Immune system ,Neoplasms ,medicine ,Humans ,Seroconversion ,Neutralizing antibody ,Aged ,Aged, 80 and over ,Chemotherapy ,biology ,SARS-CoV-2 ,business.industry ,Immunogenicity ,COVID-19 ,Cancer ,General Medicine ,Middle Aged ,medicine.disease ,Vaccination ,Vaccines, Inactivated ,Oncology ,Inactivated vaccine ,Immunology ,biology.protein ,Female ,cancer patients ,business ,Research Article - Abstract
ObjectivePatients with malignancy suffer from a compromised immune system due to either the effects of malignancies or treatments. Cancer patients are at higher risk of different infections particularly SARS-CoV2 and usually produce weaker response to vaccines. The aim of this study was to evaluate the safety and immunogenicity of the inactivated SARS-CoV-2 vaccine (Sinopharm, BBIBP-CorV) in patients with malignancy.Material and MethodIn total 364 patients with cancer (median age: 54 years old, F/M ratio: 217/147) who received two doses of Sinopharm vaccine were enrolled in this study. Vaccine related side effects was assessed by a questionnaire and the presence of SARS-CoV-2 anti-Spike protein (S) IgG and neutralizing antibody two months following vaccination were measured by immunological methods.ResultsInjection site pain and fever were the most common local and systemic side effects in vaccine receivers. Two months after the first dose, anti-S IgG and neutralizing antibody were detectable in 77.1% and 80.7% of all participants, respectively with an overall response to either or both measured in 86.9% of patients The rate of seroconversion was lower in older age, those with hematological malignancies and chemotherapy receivers.ConclusionThe result of study confirmed the safety and short-term efficacy of Sinopharm inactivated vaccine (BBIBP-CorV) in patients with different type of malignancies.
- Published
- 2021
- Full Text
- View/download PDF